Hepcidin Levels in Periodontal Health and Disease

Periodontal Diseases Clinical Trial

Official title:

Gingival Crevicular Fluid and Serum Levels of Hepcidin, IL-6 and IL-10 in Periodontal Health and Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03789565
• Other study ID #: hepcidin
• Status: Completed
• Start date: March 15, 2017
• Est. completion date: February 15, 2018

Study information

• Verified date: October 2019
• Source: Bulent Ecevit University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Periodontal disease refers to inflammatory disease of the periodontium caused by the host and/or pathogenic microorganisms. Anti-inflammatory and pro-inflammatory cytokines play a role in the periodontal inflammation process. The aim of this study was to evaluate the levels of hepcidin, interleukin (IL)-6, and IL-10 levels in gingival crevicular fluid (GCF) and in serum samples obtained from individuals with periodontal inflammation.

Description:

The study included 90 individuals, who were divided into three groups: periodontally healthy (PH) (n=30); gingivitis (G) (n=30); and chronic periodontitis (CP) (n=30). GCF and serum samples were obtained from each individual, and samples were evaluated using ELISA. Statistical evaluation of the data was performed using the SPSS packet data program.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: February 15, 2018
• Est. primary completion date: January 20, 2018
• Gender: All
• Age group: 32 Years to 52 Years

Eligibility

Inclusion Criteria:

• Systematically healthy patients. Patients who did not receive any medication or periodontal treatment within the previous 6 months

Exclusion Criteria:

• Individuals who smoked and women who were pregnant and/or lactating were excluded from the study

Related Conditions & MeSH terms

• Periodontal Diseases

Intervention

Other:
• Biomarker test
Diagnostic biomarker study

Locations

Country	Name	City	State
Turkey	Çigdem Coskun Türer	Zonguldak

Sponsors (1)

Lead Sponsor	Collaborator
Bulent Ecevit University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hepcidin levels	Change in inflammatory phases	1 year
Secondary	IL-6 levels	Change in inflammatory phases	1 year
Secondary	IL-10 levels	Change in inflammatory phases	1 year